Phase III study of nasal dihydroergotamine (DHE) in acute migraine fails to meet primary endpoint

In the EMERGE study, the dry-powder formulation of DHE (two doses assessed) resulted in numerical differences versus placebo in the co-primary endpoints of freedom from pain and freedom from most bothersome symptom, but they were not statistically significant.


Biospace Inc.